

TO THE SPANISH NATIONAL SECURITIES MARKET COMMISSION
(COMISIÓN NACIONAL DEL MERCADO DE VALORES)

Madrid, 29 September 2025

In compliance with the reporting requirements provided for in article 226 of the Law 6/2023, of 17 March, on the Securities Markets and Investment Services, Laboratorios Farmacéuticos Rovi, S.A. (hereinafter, “**ROVI**” or the “**Company**”) hereby discloses to the Spanish National Securities Market Commission the following

INSIDE INFORMATION

The Company announces that ROIS Phoenix Inc. (the “**Buyer**”), a wholly owned subsidiary of ROVI Pharma Industrial Services, S.A.U., has entered into an Asset Purchase Agreement with Bristol Myers Squibb (“**BMS**”) for the acquisition of a drug manufacturing facility located in Phoenix, Arizona (United States of America) (the “**Facility**”) together with a series of assets and liabilities related thereto (the “**Transaction**”).

As part of the Transaction, the Buyer has entered into a Toll Manufacturing Agreement with BMS, which regulates the conditions under which the Buyer will continue to manufacture for BMS at the Facility. The agreement has an initial term of five years from the closing of the Transaction and provides for a minimum payment of 50 million dollars for each year of the contract.

The acquisition of the Facility will be made for a price which is not material for ROVI and will be subject to the fulfilment of certain customary conditions precedent set out for this type of transaction. The completion of the Transaction is expected to take place during the first half of 2026.

Likewise, ROVI will hold a virtual meeting with analysts and investors tomorrow, September 30th, to explain the Transaction. Please find the access link in the Investor Calendar on our company website.

William Blair is serving as exclusive financial advisor to Bristol Myers Squibb.

Mr. Juan López-Belmonte Encina
President of the Board of Directors and CEO
Laboratorios Farmacéuticos ROVI, S.A.